Kirke Weaver - Mar 31, 2024 Form 4 Insider Report for Organon & Co. (OGN)

Role
Gen. Counsel & Corp. Secy.
Signature
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Kirke Weaver
Stock symbol
OGN
Transactions as of
Mar 31, 2024
Transactions value $
-$72,982
Form type
4
Date filed
4/3/2024, 06:40 PM
Previous filing
Apr 2, 2024
Next filing
May 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OGN Common Stock Options Exercise $0 +4.29K +23.17% $0.00 22.8K Mar 31, 2024 Direct
transaction OGN Common Stock Tax liability -$23K -1.22K -5.36% $18.80 21.6K Mar 31, 2024 Direct
transaction OGN Common Stock Options Exercise $0 +6.2K +28.7% $0.00 27.8K Mar 31, 2024 Direct
transaction OGN Common Stock Tax liability -$33.2K -1.77K -6.36% $18.80 26K Mar 31, 2024 Direct
transaction OGN Common Stock Options Exercise $0 +3.13K +12% $0.00 29.2K Mar 31, 2024 Direct
transaction OGN Common Stock Tax liability -$16.8K -891 -3.06% $18.80 28.3K Mar 31, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Restricted Stock Units Options Exercise $0 -4.29K -50% $0.00 4.29K Mar 31, 2024 Common Stock 4.29K Direct F1, F2
transaction OGN Restricted Stock Units Options Exercise $0 -3.13K -50% $0.00 3.13K Mar 31, 2024 Common Stock 3.13K Direct F1, F2, F3
transaction OGN Restricted Stock Units Options Exercise $0 -6.2K -33.33% $0.00 12.4K Mar 31, 2024 Common Stock 6.2K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock.
F2 The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025.
F3 The Reporting Person was granted RSUs on November 7, 2022, which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025.
F4 The Reporting Person was granted RSUs on March 31, 2023. On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026.